News for Abcam PLC

PR Newswire 10d

Abcam to Report Full Year Results on Monday, March 20, 2023

Investegate 96d

AIM : Cancellation - Abcam Plc

PR Newswire 98d

Abcam plc: Update on AIM Delisting

Investegate 98d

ABCAM PLC : Update on AIM Delisting

Investegate 110d

ABCAM PLC : Total Voting Rights

Investegate 112d

ABCAM PLC : Director/PDMR Shareholding - Correction

Investegate 122d

ABCAM PLC : Director/PDMR Shareholding

PR Newswire 128d

ABCAM PLC: Result of General Meeting - Shareholders approve AIM Delisting

Investegate 129d

ABCAM PLC : Result of General Meeting

Investegate 140d

ABCAM PLC : Total Voting Rights

Investegate 154d

ABCAM PLC : Proposed cancellation of AIM shares & notice of GM

Investegate 161d

ABCAM PLC : Director/PDMR Shareholding

Investegate 170d

ABCAM PLC : Block Listing Six Monthly Return

Investegate 170d

ABCAM PLC : Total Voting Rights

Investegate 189d

ABCAM PLC : Interim results for the period ended 30 June 2022

Seeking Alpha 189d

Abcam ADS Non-GAAP EPS of 14.00p, revenue of £185.2M

Investegate 189d

ABCAM PLC : Appointment of Non-Executive Director

Investegate 201d

ABCAM PLC : Total Voting Rights

Investegate 215d

ABCAM PLC : Notice of Results

Investegate 234d

ABCAM PLC : Total Voting Rights

Financial Times 242d

Cambridge biotech Abcam to abandon London listing for Nasdaq

Financial Times 242d

Cambridge biotech Abcam to abandon London listing for Nasdaq

Investegate 243d

ABCAM PLC : Trading Statement

PR Newswire 266d

Abcam: Appointment of Vice President of Investor Relations

Investegate 292d

ABCAM PLC : Total Voting Rights

Investegate 305d

ABCAM PLC : Result of AGM

Investegate 324d

ABCAM PLC : Total Voting Rights

Investegate 348d

ABCAM PLC : Director/PDMR Shareholding

Investegate 350d

ABCAM PLC : Publication of 2021 ARA and Notice of AGM

Investegate 354d

ABCAM PLC : Total Voting Rights

Investegate 355d

ABCAM PLC : Block listing Interim Review

Investegate 357d

ABCAM PLC : Block Listing application of Ordinary Shares

Zacks 367d

Wall Street Analysts Predict a 27% Upside in Abcam PLC Sponsored ADR (ABCM): Here's What You Should Know

GlobeNewswire 371d

Abcam Plc Results for the 12- and 18-month periods ended 31 December 2021

GlobeNewswire 553d

29% Constant Currency Revenue Growth in H2 as Lab Activity Gradually Recovers and Demand for Abcam In-house Products Increases

GlobeNewswire 595d

Abcam to Acquire BioVision for $340 million

Seeking Alpha 615d

Abcam opens new facility in Boston, Massachusetts

PR Newswire 636d

Pionyr and Abcam extend partnership to evaluate TREM2-expressing cells in cancer patients

PR Newswire 636d

Pionyr and Abcam extend partnership to evaluate TREM2-expressing cells in cancer patients

GlobeNewswire 707d

Abcam and MEDx extend precision medicine strategic partnership

GlobeNewswire 726d

Abcam Wins Industry Awards from CiteAb

GlobeNewswire 742d

8.3% constant currency revenue growth in H1 as customers gradually return to labs

Seeking Alpha 742d

Abcam plc reports 1H results

GlobeNewswire 746d

Abcam Expands Presence in China to Support Increased Demand of BioPharma Sector

GlobeNewswire 752d

Abcam to Report Interim Results on Monday, March 8, 2021

GlobeNewswire 761d

Abcam to present at the 2021 SVB Leerink Global Healthcare Conference

GlobeNewswire 781d

Abcam Plc Appointment of Non-Executive Directors

GlobeNewswire 798d

Abcam plc Half Year Trading Update

GlobeNewswire 867d

Abcam plc: Annual Report, Impact Report and Notice of AGM

GlobeNewswire 867d

Abcam plc: Consultation on 2020 LTIP Awards